add directory ♦ physician job search
Today's News:
All Neurology Jobs
Permanent Neurology Job in Portland Oregon with Providence Health & Services
Portland, Oregon -- Providence Health & Services is seeking an excellent Stroke Neurologist to join us in an active neurological practice. Ideally seeking a Neurointensive Care Specialist; Vascular Neurologist
Permanent Neurology Job in Anchorage Alaska with Providence Health & Services
Anchorage, Alaska -- Providence Alaska Medical Center is seeking a behavioral neurologist, psychiatrist or neuropsychiatrist to join our Neuropsychiatry Services Department. Will share duties with another
Permanent Neurology Job in Walla walla Washington with Providence Health & Services
St. Mary Medical Center in Walla Walla, Washington, is seeking an outstanding neurologist specializing in EEG, and EMG to join our top-rated hospital. General practice, shared call in the community is
Archives of Neurology recent issues
NEUROLOGICAL REVIEW: Blood Protein Signature for the Early Diagnosis of Alzheimer Disease
Britschgi, M., Wyss-Coray, T. Mon, 08 Dec 2008 00:00:00 -0000
Alzheimer disease (AD) has become one of the main health concerns for the elderly population in the United States. Current treatments target symptoms only, but several advanced clinical trials are testing new drugs that are potentially disease modifying. Because AD is still difficult to diagnose in its earliest stages and the disease process is estimated to start many years before current clinical diagnosis is made, accurate and simple diagnostic tools are urgently needed. We recently described a blood-based panel of secreted signaling proteins that distinguishes between blinded samples from patients with AD and control subjects with high accuracy. The same proteins also predicted progression to AD in preclinical patients with mild cognitive impairment several years before clinical diagnosis for AD was made. Herein, we describe these findings and discuss the potential for a more general application of our proteomic approach in understanding and diagnosing disease.Published online December 8, 2008 (doi:10.1001/archneurol.2008.530).
ORIGINAL CONTRIBUTION: Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study
Chiu, A. W., Richert, N., Ehrmantraut, M., Ohayon, J., Gupta, S., Bomboi, G., Gaindh, D., Cantor, F. K., Frank, J. A., McFarland, H. F., Bagnato, F. Mon, 10 Nov 2008 00:00:00 -0000
Objectives To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.Design, Setting, and Patients Fifteen patients with relapsing-remitting multiple sclerosis underwent monthly MRIs and clinical examinations (6-month pretherapy phase and 36-month therapy phase) and bimonthly neutralizing antibody tests. On each MRI, the total number of contrast-enhancing lesions was noted. Therapy MRI responders were defined as those with a reduction of 60% or more in the total number of contrast-enhancing lesions during each semester of therapy.Intervention Subcutaneous administration of interferon beta-1b, 250 µg, every other day for 3 years.Main Outcome Measure Reduction in the number of contrast-enhancing lesions.Results Eight patients (53.3%) were MRI responders and 7 (46.7%) were nonresponders. Of those 7, 3 (20.0%) had only an initial optimal reduction of the total number of contrast-enhancing lesions, 2 (13.3%) never reached an optimal response, and 2 (13.3%) had a delayed optimal response. No clear association between neutralizing antibody profile and MRI response was evident.Conclusions Multiple MRI evaluations disclose that approximately only half of the patients treated with interferon beta achieve and maintain a full response to the drug over time, although an additional small number of individuals may still restore an optimal response to the drug after an initial failure.Published online November 10, 2008 (doi:10.1001/archneur.66.1.noc80047).
ABOUT THIS JOURNAL: About This Journal
Mon, 08 Dec 2008 00:00:00 -0000
Subscribe to Clinical_Neurophysiology RSS feed 
Permanent Neurology Job in Portland Oregon with Providence Health & Services
Portland, Oregon -- Providence Health & Services is seeking an excellent Stroke Neurologist to join us in an active neurological practice. Ideally seeking a Neurointensive Care Specialist; Vascular Neurologist
Permanent Neurology Job in Anchorage Alaska with Providence Health & Services
Anchorage, Alaska -- Providence Alaska Medical Center is seeking a behavioral neurologist, psychiatrist or neuropsychiatrist to join our Neuropsychiatry Services Department. Will share duties with another
Permanent Neurology Job in Walla walla Washington with Providence Health & Services
St. Mary Medical Center in Walla Walla, Washington, is seeking an outstanding neurologist specializing in EEG, and EMG to join our top-rated hospital. General practice, shared call in the community is
Archives of Neurology recent issues
NEUROLOGICAL REVIEW: Blood Protein Signature for the Early Diagnosis of Alzheimer Disease
Britschgi, M., Wyss-Coray, T. Mon, 08 Dec 2008 00:00:00 -0000
Alzheimer disease (AD) has become one of the main health concerns for the elderly population in the United States. Current treatments target symptoms only, but several advanced clinical trials are testing new drugs that are potentially disease modifying. Because AD is still difficult to diagnose in its earliest stages and the disease process is estimated to start many years before current clinical diagnosis is made, accurate and simple diagnostic tools are urgently needed. We recently described a blood-based panel of secreted signaling proteins that distinguishes between blinded samples from patients with AD and control subjects with high accuracy. The same proteins also predicted progression to AD in preclinical patients with mild cognitive impairment several years before clinical diagnosis for AD was made. Herein, we describe these findings and discuss the potential for a more general application of our proteomic approach in understanding and diagnosing disease.Published online December 8, 2008 (doi:10.1001/archneurol.2008.530).
ORIGINAL CONTRIBUTION: Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study
Chiu, A. W., Richert, N., Ehrmantraut, M., Ohayon, J., Gupta, S., Bomboi, G., Gaindh, D., Cantor, F. K., Frank, J. A., McFarland, H. F., Bagnato, F. Mon, 10 Nov 2008 00:00:00 -0000
Objectives To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.Design, Setting, and Patients Fifteen patients with relapsing-remitting multiple sclerosis underwent monthly MRIs and clinical examinations (6-month pretherapy phase and 36-month therapy phase) and bimonthly neutralizing antibody tests. On each MRI, the total number of contrast-enhancing lesions was noted. Therapy MRI responders were defined as those with a reduction of 60% or more in the total number of contrast-enhancing lesions during each semester of therapy.Intervention Subcutaneous administration of interferon beta-1b, 250 µg, every other day for 3 years.Main Outcome Measure Reduction in the number of contrast-enhancing lesions.Results Eight patients (53.3%) were MRI responders and 7 (46.7%) were nonresponders. Of those 7, 3 (20.0%) had only an initial optimal reduction of the total number of contrast-enhancing lesions, 2 (13.3%) never reached an optimal response, and 2 (13.3%) had a delayed optimal response. No clear association between neutralizing antibody profile and MRI response was evident.Conclusions Multiple MRI evaluations disclose that approximately only half of the patients treated with interferon beta achieve and maintain a full response to the drug over time, although an additional small number of individuals may still restore an optimal response to the drug after an initial failure.Published online November 10, 2008 (doi:10.1001/archneur.66.1.noc80047).
ABOUT THIS JOURNAL: About This Journal
Mon, 08 Dec 2008 00:00:00 -0000
Sites:
Botox Information: Offers details for persons considering a treatment with Botox or Myobloc. Various uses of Botox are discussed, along with information on pricing and scheduling.Clinical Neurophysiology on the Internet: Internet resources on clinical neurophysiology
CliniLab: Specialised in diagnostic hospital equipment and accessories.
EMG in the diagnosis of Nerve and Muscle diseases: Online EMG manual with active discussion groups.
Evoked Potential: Evoked Potentials or Responses assist in diagnosis of Multiple sclerosis and other diseases.
International Federation of Clinical Neurophysiology: Non-profit world-wide federation of clinical neurophysiologists.
Neuro Traces: Neurotraces is dedicated to Clinical Neurophysiology (EEG, EMG, EP and sleep recording)
Pittsburgh Medical Center: Center for Clinical Neurophysiology (CCN) provides diagnostic testing through a number of member and associated laboratories, intraoperative monitoring at hospitals throughout the tri-state region, and continuous intensive care unit monitoring at these hospitals' ICUs.
This directory is based on the Open Directory and may have been modified